



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/47, 16/18, G01N 33/566, C12Q 1/68, C12N 15/11, 15/62, A01K 67/027, A61K 38/00		A2	(11) International Publication Number: WO 00/58473
			(43) International Publication Date: 5 October 2000 (05.10.00)
(21) International Application Number: PCT/US00/08621		(72) Inventors; and	
(22) International Filing Date: 31 March 2000 (31.03.00)		(75) Inventors/Applicants (<i>for US only</i>): SHIMKETS, Richard, A. [US/US]; 191 Leete Street, West Haven, CT 06516 (US). LEACH, Martin [GB/US]; 884 School Street, Webster, MA 01570 (US).	
(30) Priority Data:		(74) Agent: ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).	
60/127,607 31 March 1999 (31.03.99) US 60/127,636 2 April 1999 (02.04.99) US 60/127,728 5 April 1999 (05.04.99) US 09/540,763 30 March 2000 (30.03.00) US			
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
US 60/127,607 (CIP) Filed on 31 March 1999 (31.03.99) US 60/127,636 (CIP) Filed on 2 April 1999 (02.04.99) US 60/127,728 (CIP) Filed on 5 April 1999 (05.04.99) US 09/540,763 (CIP) Filed on 30 March 2000 (30.03.00)		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(71) Applicant (<i>for all designated States except US</i>): CURAGEN CORPORATION [US/US]; 555 Long Wharf Drive, 11th Floor, New Haven, CT 06511 (US).			
(54) Title: NUCLEIC ACIDS INCLUDING OPEN READING FRAMES ENCODING POLYPEPTIDES; "ORFX"			
(57) Abstract			
<p>The present invention provides open reading frames ORFX, encoding isolated polypeptides, as well as polynucleotides encoding ORFX and antibodies that immunospecifically bind to ORFX or any derivative, variant, mutant, or fragment of the ORFX polypeptides, polynucleotides or antibodies. The invention additionally provides methods in which the ORFX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

accgggtcagt ctgcgcggca gcaccgcacc ccggagccgc agctcttctt cccgcttgcc
 60
 cgacagccct ggtgccaagc cctgtctgag cccaccagg aggaagcgcg tgctggctgc
 120
 tctccatctg ctctgggact ctggcctgct gcttctcttg cctgccactc cccaaccccg
 180
 tttctctctc tgaaaactgg agctacacct gcccacacag ggcagaatta ccttaaattg
 240
 cacaagacaa ttgcacagca gaccacctc ttctccaaag ttttcagggc ccaaaccag
 300
 acacctctt gcaggactca tggctaccgt gggctcgac caccagctc cccatgcgtt
 360
 ttctcgctc tgcttttgct caatctgctc aatgacagaa acgcgacaac agagggcact
 420
 ttctccaaac ccagctctcc ctcgaggctc ccctctgct gctcacgctg agggcactct
 480
 accctgcct ccgcagctca caggcagacc tggagcccag tgactacagg gttggcctcc
 540
 tcatcttgcc accactcaca atgccagca gtgttaaaat ccggcaggat gcacccgctt
 600
 gggaagcagt ccccaaagca gaatcgtcac cacatctgaa tagtttctgc catccactg
 660
 acaggccagc atctaaaaga gatgtgcgt gagcgctcgt tatgtggtgg cgctcgctgtg
 720
 gtttcttaac cagaacgcaa aatcctgtga ccaggattat caccggctcg tttcatacat
 780
 gagacggggg aagccaaagt aaccactcag gccacagcag aaaaacgcgt
 830

<210> 2520

<211> 107

<212> PRT

<213> Homo sapiens

<400> 2520

Met	Ser	Pro	Ala	Arg	Arg	Cys	Leu	Gly	Leu	Gly	Pro	Glu	Asn	Phe	Gly
1				5				10						15	
Glu	Glu	Val	Gly	Leu	Leu	Cys	Asn	Cys	Leu	Val	Pro	Phe	Lys	Val	Ile
			20				25						30		
Leu	Pro	Cys	Trp	Gly	Arg	Cys	Ser	Ser	Ser	Phe	Gln	Arg	Arg	Lys	Arg
		35				40					45				
Gly	Trp	Gly	Val	Ala	Gly	Arg	Gly	Ser	Ser	Arg	Pro	Glu	Ser	Gln	Ser
		50				55					60				
Arg	Trp	Arg	Ala	Ala	Ser	Thr	Arg	Phe	Leu	Leu	Val	Gly	Leu	Arg	Gln
65					70				75					80	
Gly	Leu	Ala	Pro	Gly	Leu	Ser	Gly	Lys	Arg	Glu	Glu	Glu	Leu	Arg	Leu
				85				90						95	
Arg	Gly	Ala	Val	Leu	Pro	Arg	Arg	Leu	Thr	Gly					
			100					105							

<210> 2521

<211> 4291

<212> DNA

<213> Homo sapiens

<400> 2521
ctctctctct ttcggggegga gtcgcccacc actgccagcc cagcgctggg gggacctgct
60
ccaggtctga gccgcaggac cccaccaccc cccatggctc ccctggcctt ggtgggggtc
120
acactcctcc tggcggtccc cccatgctcc ggggcagcca ccccaacccc ctccctgccg
180
cctcccccg ccaatgacag cgacaccagc acagggggct gccaggggtc ctaccgctgc
240
cagccggggg tgctgctgcc cgtgtgggag cccgacgacc cgtcgctggg tgacaaggcg
300
gcacgggcag tgggtgactt tgtggccatg gtctacatgt ttctgggagt gtccatcatc
360
gccgaccgtt tcatggcggc catcgaggct atcacgtcaa aagagaagga gatcaccatc
420
accaaggcca acggtgagac cagcgtgggc accgttcgca tctggaatga gacgggtgtcc
480
aacctcacgc tcatggccct gggctcctcc gcacctgaga tctgtgtgc agtcatcgaa
540
gtctgcgccc acaacttcca ggcgggtgag ctgggcccag gcaccatcgt gggcagcgct
600
gccttcaaca tgtttgtggt catcgccgtg tgcattctacg tcatcccagc cggcgagagc
660
cgcaagatca agcacctgag agtcttcttt gtcactgcct cttggagcat cttgcctat
720
gtctggcttt atctcatcct tgctgttttt tccccgggtg tgggtccagggt gtgggaggcg
780
ctgctgaccc tgggtcttctt cccgggtgtgc gtggtattcg cctggatggc cgacaagcgg
840
ctgctcttct acaagtagt gtacaagcgc taccgcaccg acccacgcag cggcatcatc
900
ataggcgccc agggcgaccc cccgaagagc atcgagctgg acggcacggt cgtgggcgcc
960
gaggccccag gtgagctggg cggcctgggc ccgggccccg ccgaggcgcg cgagctggac
1020
gccagccgcc gcgagggtcat ccagatcctc aaggacctca agcagaagca cccggacaag
1080
gatctggagc agctgggtggg catcgccaac tactacgcgc tgctgcacca gcagaagagc
1140
cgcgcttctt accgcatcca ggccacgcgg ctgatgaccg gcgccgggaa cgtgctgcgc
1200
agacacgcgg cggacgcctc gcgcagggcg gcgccggccg agggcgcggg cgaggacgaa
1260
gacgacggcg ccagccgcat cttcttcgag cctagcctct accactgcct ggagaactgc
1320
ggctccgtgc tgetgtccgt cacgtgccag ggcggcgagg gcaacagcac cttctacgtg
1380
gactaccgca ctgaggacgg ctctgccaaag gcgggctccg actacgagta cagcgagggc
1440
acgctggtgt tcaaaccagg cgagacgcag aaggagctgc gcatcggcat catcgacgac
1500
gacatcttcg aggaggacga gcatttcttc gtgcggctgc tgaacctgcg cgtgggcgac
1560

gcgcagggca tgttcgagcc ggacggcggc gggcgggcca agggcgggct ggtggcgccg
1620
ctgctggcca ccgtcaccat cctggacgac gaccacgcag gcattcttctc cttccaggac
1680
cgctgctgc acgtgagcga gtgcatgggc accgtggacg tgcgcgtcgt gcgcagctcg
1740
ggcgcgcgcg gcaccgtgcg ccttccctac cgcacgggtgg acggcacggc gcgcggcgcg
1800
ggcgtgcact acgaggacgc gtgcgagagag ctggagtctg gcgacgacga gaccatgaaa
1860
actcttcagg tgaagatagt tgatgacgag gaatatgaga aaaaggataa tttcttcatt
1920
gagctggggc agccccagtg gcttaagcga gggatttcag ctctgctact caatcaaggg
1980
gatggggaca ggaagctaac agccgaggag gaggaggctc ggaggatagc agagatgggc
2040
aagccagttc ttggggagaa ctgccggctg gaggtcatca tcgaggagtc atatgatttt
2100
aagaacacgg tggataaact catcaagaaa acgaacttgg ccttggtaat tgggacctat
2160
tcatggaggg agcagttttt agaggcaatt acggtgagcg caggggacga ggaggaggag
2220
gaggacgggt cccgggagga gggctgccc tctgtctttg actacgtgat gcacttcctg
2280
acggtgttct ggaaggtgct cttcgctgt gtgccccca ccgagtactg ccacggctgg
2340
gcctgctttg gtgtctccat cctggctcgc ggctgctca ccgccctcat tggggacctc
2400
gcctccact tcggctgcac cgttggcctc aaggactctg tcaatgctgt tgtcttcgtt
2460
gccctgggca cctccatccc tgacacgttc gccagcaagg tggcgcgct gcaggaccag
2520
tgcgcgcgac cgtccatcgg caacgtgacc ggctccaacg cggtgaaact gtctcctggc
2580
ctggcgctcg cctggctctgt ggccgcctg tactggggcg tgcagggccg ccccttcgag
2640
gtgcgcactg gcacgctggc cttctcctgc acgctcttca ccgtcttcgc cttcgtgggc
2700
attgccgtgc tgcgtaccg gcgcgggccc cacatcggcg gcgagctggg cggcccgcg
2760
ggaccaage tcgccaccac cgcgtctctc ctgggcctct ggctcctgta catcctcttc
2820
gccagcctgg aggcgtactg ccacatccgg ggcttctagg gcctcgcgca gagactcgtc
2880
cccaccgccc gcccggggct agggactcgg ctgcacctgc tcttggaacc tggctctcct
2940
ttccccccag actcggcctc ctctcctggg actcggcctc ccttctccgc cccctccct
3000
ggctttgatt gcccctgttc tgtgtcccca gtagctcagc ctccctctt cctctcggga
3060
gcctccccgg ttctctccct gcggtgacct caactccagc ccatcctgtt ggtgaccgtc
3120
tatatcctg gggaaatttc caccacagtc cctccccag ggaaccaccc ccagtaacca
3180

tcctgggggag tttaaggtct ctctccttgg tcaccagcc tggttttgc cccaaagtct
 3240
 ccttccccct agtgaccccc ccccaactca ccccatgtcc cagagcctca gaaccacccc
 3300
 tccttggggg accctcgaag gaggtgtca gaggcgtct cagctcccag ccttcccccc
 3360
 cagccctcag ggagctccgc tcagccccgg cggggaggag cgggtgggtg tgcgcgcaag
 3420
 gaggcgcac acctttcctt ccaatccctc cactcgggtt cttgggagga cactcattct
 3480
 ccaggctcgg agacgagggg agaagtttgg ggtttcagtc ccagggtta gccggaggaa
 3540
 gcacattttg aacctgcaac ttcagacatt ccagctcccc cactcgccct ccactacctc
 3600
 tgagagccca gccacgcctt ggaggggagg gcttgttgt gtatatagt tgtttggggg
 3660
 aggggggacg cgggaggggt catgtcttgg gaaaaggggg tgacagacaa cttttgagag
 3720
 ggcagcgac tccctcagcc atgagaacca gctttgggga ggaggccggg aatcaaagcg
 3780
 agtccagttg atctcccctg acaatctgga aggttcattt tgccctcagt gccagccaat
 3840
 ccgggcagga ccctcgaaga ggagaccgag ggtcccagag gaccaatgct acaagccagc
 3900
 aaatgctgcc acatctctgc ctgatggggg gtgggggatgg gtggggggat gggactgggc
 3960
 caagggatct ggggtgggcat ttttaacttt ggaggccttc catctgtcgg taggcatct
 4020
 gcattttctt actggtgatg tttcctgccc aaaggacaca tttgggcagt gccacccact
 4080
 ccttggggcc ctaggatgac ccaactaccc ccataacttt ctgcttccca caggttttca
 4140
 gcattctatc gtctgttgt gctcagcccc aacatcccag acccgttacc cgtaccctt
 4200
 ctctccccca gctcatcatc agtcgtgtc tctttctgt gatttctgta aaagttgcca
 4260
 taaaactttg aaattctgcc tgaaaaaaaa a
 4291

<210> 2522

<211> 952

<212> PRT

<213> Homo sapiens

<400> 2522

Leu	Ser	Leu	Phe	Arg	Ala	Glu	Ser	Pro	Thr	Thr	Ala	Ser	Pro	Ala	Leu
1			5					10						15	
Gly	Gly	Pro	Ala	Pro	Gly	Cys	Ser	Arg	Arg	Thr	Pro	Pro	Pro	Pro	Met
			20					25					30		
Ala	Pro	Leu	Ala	Leu	Val	Gly	Val	Thr	Leu	Leu	Leu	Ala	Ala	Pro	Pro
			35				40					45			
Cys	Ser	Gly	Ala	Ala	Thr	Pro	Thr	Pro	Ser	Leu	Pro	Pro	Pro	Pro	Ala
	50					55				60					
Asn	Asp	Ser	Asp	Thr	Ser	Thr	Gly	Gly	Cys	Gln	Gly	Ser	Tyr	Arg	Cys

65					70					75				80
Gln	Pro	Gly	Val	Leu	Leu	Pro	Val	Trp	Glu	Pro	Asp	Asp	Pro	Ser
				85					90				95	
Gly	Asp	Lys	Ala	Ala	Arg	Ala	Val	Val	Tyr	Phe	Val	Ala	Met	Val
			100					105					110	
Met	Phe	Leu	Gly	Val	Ser	Ile	Ile	Ala	Asp	Arg	Phe	Met	Ala	Ile
		115					120					125		
Glu	Val	Ile	Thr	Ser	Lys	Glu	Lys	Glu	Ile	Thr	Ile	Thr	Lys	Asn
	130					135					140			
Gly	Glu	Thr	Ser	Val	Gly	Thr	Val	Arg	Ile	Trp	Asn	Glu	Thr	Ser
145					150				155					160
Asn	Leu	Thr	Leu	Met	Ala	Leu	Gly	Ser	Ser	Ala	Pro	Glu	Ile	Leu
			165					170					175	
Ser	Val	Ile	Glu	Val	Cys	Gly	His	Asn	Phe	Gln	Ala	Gly	Glu	Leu
		180						185					190	
Pro	Gly	Thr	Ile	Val	Gly	Ser	Ala	Ala	Phe	Asn	Met	Phe	Val	Ile
	195					200					205			
Ala	Val	Cys	Ile	Tyr	Val	Ile	Pro	Ala	Gly	Glu	Ser	Arg	Lys	Lys
	210					215					220			
His	Leu	Arg	Val	Phe	Phe	Val	Thr	Ala	Ser	Trp	Ser	Ile	Phe	Tyr
225					230				235					240
Val	Trp	Leu	Tyr	Leu	Ile	Leu	Ala	Val	Phe	Ser	Pro	Gly	Val	Gln
			245					250					255	
Val	Trp	Glu	Ala	Leu	Leu	Thr	Leu	Val	Phe	Phe	Pro	Val	Cys	Val
		260					265					270		
Phe	Ala	Trp	Met	Ala	Asp	Lys	Arg	Leu	Leu	Phe	Tyr	Lys	Tyr	Tyr
	275					280					285			
Lys	Arg	Tyr	Arg	Thr	Asp	Pro	Arg	Ser	Gly	Ile	Ile	Ile	Gly	Glu
	290				295					300				
Gly	Asp	Pro	Pro	Lys	Ser	Ile	Glu	Leu	Asp	Gly	Thr	Phe	Val	Ala
305				310					315					320
Glu	Ala	Pro	Gly	Glu	Leu	Gly	Gly	Leu	Gly	Pro	Gly	Pro	Ala	Glu
			325					330					335	
Arg	Glu	Leu	Asp	Ala	Ser	Arg	Arg	Glu	Val	Ile	Gln	Ile	Leu	Asp
		340					345					350		
Leu	Lys	Gln	Lys	His	Pro	Asp	Lys	Asp	Leu	Glu	Gln	Leu	Val	Gly
	355					360					365			
Ala	Asn	Tyr	Tyr	Ala	Leu	Leu	His	Gln	Gln	Lys	Ser	Arg	Ala	Tyr
	370				375				380					
Arg	Ile	Gln	Ala	Thr	Arg	Leu	Met	Thr	Gly	Ala	Gly	Asn	Val	Arg
385				390					395					400
Arg	His	Ala	Ala	Asp	Ala	Ser	Arg	Arg	Ala	Ala	Pro	Ala	Glu	Gly
			405					410					415	
Gly	Glu	Asp	Glu	Asp	Asp	Gly	Ala	Ser	Arg	Ile	Phe	Phe	Glu	Ser
		420				425						430		
Leu	Tyr	His	Cys	Leu	Glu	Asn	Cys	Gly	Ser	Val	Leu	Leu	Ser	Thr
	435					440				445				
Cys	Gln	Gly	Gly	Glu	Gly	Asn	Ser	Thr	Phe	Tyr	Val	Asp	Tyr	Thr
	450				455					460				
Glu	Asp	Gly	Ser	Ala	Lys	Ala	Gly	Ser	Asp	Tyr	Glu	Tyr	Ser	Gly
465				470					475					480
Thr	Leu	Val	Phe	Lys	Pro	Gly	Glu	Thr	Gln	Lys	Glu	Leu	Arg	Gly
			485					490					495	
Ile	Ile	Asp	Asp	Asp	Ile	Phe	Glu	Glu	Asp	Glu	His	Phe	Phe	Arg

1809

930 935 940
 Ala Tyr Cys His Ile Arg Gly Phe
 945 950

<210> 2523
 <211> 392
 <212> DNA
 <213> Homo sapiens

<400> 2523
 nnnattacct acgttcgcac cctgtcagga ttcgcctaca ccgcatttgt cgtggatgtc
 60
 ttcagccgaa aaattgttgg tggtgctaca cgctcgacga tgcgtaccga tgcgtgccc
 120
 atggaggctt tggagcatgc gttaacgact gcagggcgaa ttcattggaaa ccagttaatt
 180
 caccatagcg atcggggcag ccagtacgtg tcaactgaagt attccaccgc gtttagcggaa
 240
 tccggaatcc gtccgagtgt gggaacagtc ggcgattctt atgacaatgc tctagccgaa
 300
 acagtcaacg gtctctacaa ggcggaactg attcatgccc aagggtccgtg gacgtcggtc
 360
 ggagaagtcg aattggccac cttgcggnnn nn
 392

<210> 2524
 <211> 130
 <212> PRT
 <213> Homo sapiens

<400> 2524
 Xaa Ile Thr Tyr Val Arg Thr Leu Ser Gly Phe Ala Tyr Thr Ala Phe
 1 5 10 15
 Val Val Asp Val Phe Ser Arg Lys Ile Val Gly Val Ala Thr Arg Ser
 20 25 30
 Thr Met Arg Thr Asp Ala Leu Pro Met Glu Ala Leu Glu His Ala Leu
 35 40 45
 Thr Thr Ala Gly Arg Ile His Gly Asn Gln Leu Ile His His Ser Asp
 50 55 60
 Arg Gly Ser Gln Tyr Val Ser Leu Lys Tyr Ser Thr Ala Leu Ala Glu
 65 70 75 80
 Ser Gly Ile Arg Pro Ser Val Gly Thr Val Gly Asp Ser Tyr Asp Asn
 85 90 95
 Ala Leu Ala Glu Thr Val Asn Gly Leu Tyr Lys Ala Glu Leu Ile His
 100 105 110
 Ala Gln Gly Pro Trp Thr Ser Val Gly Glu Val Glu Leu Ala Thr Leu
 115 120 125
 Arg Xaa
 130

<210> 2525
 <211> 378
 <212> DNA
 <213> Homo sapiens

What is claimed is:

1. An isolated nucleic acid molecule encoding a polypeptide comprising an amino acid sequence that is at least 85% identical to a polypeptide including an amino acid sequence selected from the group consisting of SEQ ID NO:2 n , wherein n is any integer 1-3161, or the complement thereof.
2. The isolated nucleic acid molecule of claim 1, said molecule hybridizing under stringent conditions to a nucleic acid sequence complementary to a nucleic acid molecule comprising the sequence of nucleotides selected from the group consisting of SEQ ID NO:2 n , wherein n is any integer 1-3161, or the complement thereof.
3. The isolated nucleic acid molecule of claim 1, said molecule encoding a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2 n , wherein n is any integer 1-3161, or an amino acid sequence comprising one or more conservative substitutions in the amino acid sequence selected from the group consisting of SEQ ID NO: 2 n .
4. The isolated nucleic acid molecule of claim 1, wherein said molecule encodes a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2 n , wherein n is any integer 1-3161.
5. The isolated nucleic acid molecule of claim 1, wherein said molecule comprises the sequence of nucleotides selected from the group consisting of SEQ ID NO:2 n -1, wherein n is any integer 1-3161, or the complement thereof.
6. An oligonucleotide less than 100 nucleotides in length and comprising at least contiguous nucleotides selected from the group consisting of SEQ ID NO:2 n -1, wherein n is any integer 1-3161, or the complement thereof.
7. A vector comprising the nucleic acid molecule of claim 1.

8. The vector of claim 7, wherein said vector is an expression vector.
9. A host cell comprising the isolated nucleic acid molecule of claim 1.
10. A substantially purified polypeptide comprising an amino acid sequence at least 80% identical to a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2*n*, wherein *n* is any integer 1-3161.
11. The polypeptide of claim 10, wherein said polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 2*n*, wherein *n* is any integer 1-3161.
12. An antibody that selectively binds to the polypeptide of claim 10.
13. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of a therapeutic selected from the group consisting of:
 - a) the nucleic acid of claim 1;
 - b) the polypeptide of claim 10; and
 - c) the antibody of claim 12;and a pharmaceutically acceptable carrier.
14. A kit comprising in one or more containers, a therapeutically or prophylactically effective amount of the pharmaceutical composition of claim 13.
15. A method of producing the polypeptide of claim 10, said method comprising culturing the host cell of claim 9 under conditions in which the nucleic acid molecule is expressed.
16. A method of detecting the presence of the polypeptide of claim 10 in a sample, comprising contacting the sample with a compound that selectively binds to said polypeptide under conditions allowing the formation of a complex between said polypeptide and said

compound, and detecting said complex, if present, thereby identifying said polypeptide in said sample.

17. A method of detecting the presence of a nucleic acid molecule of claim 1 in a sample, the method comprising contacting the sample with a nucleic acid probe or primer that selectively binds to the nucleic acid molecule and determining whether the nucleic acid probe or primer bound to the nucleic acid molecule of claim 1 is present in the sample.

18. A method for modulating the activity of the polypeptide of claim 10, the method comprising contacting a cell sample comprising the polypeptide of claim 10 with a compound that binds to said polypeptide in an amount sufficient to modulate the activity of the polypeptide.

19. The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a ORFX-associated disorder, wherein said therapeutic is selected from the group consisting of:

- a) the nucleic acid of claim 1;
- b) the polypeptide of claim 10; and
- c) the antibody of claim 12.

20. A method for screening for a modulator of activity or of latency or predisposition to an ORFX-associated disorder, said method comprising:

- a) contacting a test compound with the polypeptide of claim 10; and
- b) determining if said test compound binds to said polypeptide,

wherein binding of said test compound to said polypeptide indicates the test compound is a modulator of activity or of latency or predisposition to an ORFX-associated disorder.

21. A method for screening for a modulator of activity or of latency or predisposition to an ORFX-associated disorder, said method comprising:

- a) administering a test compound to a test subject at an increased risk ORFX-associated disorder, wherein said test subject recombinantly expresses a polypeptide encoded by the nucleotide of claim 1;

- b) measuring expression the activity of said protein in said test subject;
- c) measuring the activity of said protein in a control subject that recombinantly expresses said protein and is not at increased risk for an ORFX-associated disorder; and
- d) comparing expression of said protein in said test subject and said control subject, wherein a change in the activity of said protein in said test subject relative to said control subject indicates the test compound is a modulator or of latency of predisposition to an ORFX-associated disorder.

22. The method of claim 20, wherein said test animal is a recombinant test animal that expresses a test protein transgene or expresses said transgene under the control of a promoter at an increased level relative to a wild-type test animal, and wherein said promoter is not the native gene promoter of said transgene.

23. A method for determining the presence of or predisposition to a disease associated with altered levels of a polypeptide of claim 11 in a subject, the method comprising:

- a) measuring the amount of the polypeptide in a sample from said subject; and
- b) comparing the amount of said polypeptide in step (a) to the amount of the polypeptide present in a control sample,

wherein an alteration in the level of the polypeptide in step (a) as compared to the control sample indicates the presence of or predisposition to a disease in said subject.

24. The method of claim 23, wherein said subject is a human.

25. A method for determining the presence of or predisposition to a disease associated with altered levels the nucleic acid molecule of claim 1 in a subject, the method comprising:

- a) measuring the amount of the nucleic acid in a sample from the mammalian subject; and
- b) comparing the amount of said nucleic acid in step (a) to the amount of the nucleic acid present in a control sample,

wherein an alteration in the level of the nucleic acid in step (a) as compared to the control sample indicates the presence of or predisposition to said disease in said subject.

26. The method of claim 25, wherein said subject is a human.

27. A method of treating or preventing a pathological condition associated with an ORFX-associated disorder in a subject, the method comprising administering to said subject polypeptide of claim 10 in an amount sufficient to alleviate or prevent said pathological condition.

28. The method of claim 27, wherein said subject is a human.

29. A method of treating or preventing a pathological condition associated with an ORFX-associated disorder in a subject, the method comprising administering to said subject nucleic acid molecule of claim 1 in an amount sufficient to alleviate or prevent said pathological condition.

30. The method of claim 29, wherein said subject is a human.

31. A method of treating or preventing a pathological condition associated with an ORFX-associated disorder in a subject, the method comprising administering to said subject antibody of claim 12 in an amount sufficient to alleviate or prevent said pathological condition.

32. The method of claim 31, wherein said subject is a human.